Phospholipase A2

News and Video Search Results

News coverage

MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting

MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting

Accesswire 04 Nov 2021

*Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive..

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
PR Newswire Asia 02 Nov 2023
Propulsion of Hypertriglyceridemia Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
GlobeNewswire 14 Aug 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape
GlobeNewswire 17 Apr 2023
DelveInsight Evaluates a Robust Nonalcoholic Fatty Liver Disease Pipeline as 110+ Influential Pharma Players to Set Foot in the Domain
GlobeNewswire 02 Jan 2023

0 shares 1 views

You might like

Phospholipase A2 media coverage

MorphoSys presents interim results from M-PLACE study with felzartamab during American Society of Nephrology Annual Meeting
EQS Group 04 Nov 2021
Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
GlobeNewswire 01 Nov 2021

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021
GlobeNewswire 15 Oct 2021
Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
GlobeNewswire 03 May 2021